Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Therapeutic Advances in Medical Oncology
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sonpavde, G.
Right arrow Articles by Rosenberg, J. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Novel agents for advanced bladder cancer

Guru Sonpavde

Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, D1230, 44 Binney Street, Boston, MA 02115, USA, jonathan_rosenberg{at}dfci.harvard.edu

Aymen A. Elfiky

Genitourinary Oncology Program, Texas Oncology, Veterans Affairs Medical Center, Baylor College of Medicine, 501 Medical Center Blvd, Webster, TX 77598, USA

Jonathan E. Rosenberg

Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, D1230, 44 Binney Street, Boston, MA 02115, USA

Conventional front-line platinum-based combination chemotherapy yields high response rates but suboptimal long-term outcomes for advanced transitional cell carcinoma. Salvage therapy is an unmet need with disappointing outcomes. The emergence of novel biologic agents offers the promise of improved outcomes. Neoadjuvant therapy preceding cystectomy for muscle-invasive bladder cancer provides an important paradigm and an interesting approach in developing novel agents. Patients who are not candidates for cisplatin require special attention. A multidisciplinary approach and collaboration among laboratory scientists, oncologists, urologists and radiation oncologists is necessary to make therapeutic advances. Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed.

Key Words: transitional cell carcinoma • chemotherapy • biologic agents

References

  • Albers, P., Siener, R., Michael, R., Fechner, G., Kobalz, L., Heidenreich, A. et al. (2002) Randomized Phase II Trial of Gemcitabine and Paclitaxel with or without Maintenance Treatment in Patients with Cisplatin Refractory Transitional Cell Carcinoma. Proc Am Soc Clin Oncol 20: 797.
  • Albers, P., Siener, R., Park, S., Fechner, G., Steiner, U., Lehmann, J. et al. (2008) Randomized Phase III Trial of 2 nd Line Gemcitabine/Paclitaxel Chemotherapy in Patients with Advanced Bladder Cancer: Temporary Versus Maintenance Treatment (German Association of Urologic Oncology (Auo) Trial Ab 20/99). J Clin Oncol (Meeting Abstracts) 26: 5030.
  • Allen, L.E. and Maher, P.A. (1993) Expression of Basic Fibroblast Growth Factor and Its Receptor in an Invasive Bladder Carcinoma Cell Line. J Cell Physiol 155: 368-375.[CrossRef][Medline] [Order article via Infotrieve]
  • Ardavanis, A., Tryfonopoulos, D., Alexopoulos, A., Kandylis, C., Lainakis, G. and Rigatos, G. (2005) Gemcitabine and Docetaxel as First-Line Treatment for Advanced Urothelial Carcinoma: A Phase Ii Study. Br J Cancer 92: 645-650.[CrossRef][Medline] [Order article via Infotrieve]
  • Bajorin, D.F., Dodd, P.M., Mazumdar, M., Fazzari, M., Mccaffrey, J.A., Scher, H.I. et al. (1999) Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy. J Clin Oncol 17: 3173-3181.[Abstract/Free Full Text]
  • Bajorin, D.F., Ostrovnaya, I., Iasonos, A., Milowsky, M.I., Boyle, M. and Riches, J. (2007) A Nomogram Predicting Survival of Patients (Pts) with Metastatic or Unresectable Urothelial Cancer (Uc) Treated with Cisplatin-Based Chemotherapy. J Clin Oncol (Meeting Abstracts) 25: 5055.
  • Beecken, W.D., Engl, T., Hofmann, J., Jonas, D. and Blaheta, R. (2005) Clinical Relevance of Serum Angiogenic Activity in Patients with Transitional Cell Carcinoma of the Bladder. Journal of Cellular and Molecular Medicine 9: 655-661.[CrossRef][Medline] [Order article via Infotrieve]
  • Beer, T.M., Goldman, B., Nichols, C.R., Petrylak, D.P., Agarwal, M., Ryan, C.W. et al. (2008) Southwest Oncology Group Phase Ii Study of Irinotecan in Patients with Advanced Transitional Cell Carcinoma of the Urothelium That Progressed after Platinum-Based Chemotherapy. Clin Genitourin Cancer 6: 36-39.[CrossRef][Medline] [Order article via Infotrieve]
  • Bellmunt, J., Maroto, P., Mellado, B., Carles, J., Calvo, E., Alcaraz, A. et al. (2008) Phase II Study of Sunitinib as First Line Treatment in Patients with Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy. Genitourinary Cancer Symposium: abstract 291.
  • Bellmunt, J., Paz-Ares, L., Cuello, M., Cecere, F.L., Albiol, S., Guillem, V. et al. (2007b) Gene Expression of Ercc1 as a Novel Prognostic Marker in Advanced Bladder Cancer Patients Receiving Cisplatin-Based Chemotherapy. Ann Oncol 18: 522-528.[Abstract/Free Full Text]
  • Bellmunt, J., Ribas, A., Eres, N., Albanell, J., Almanza, C., Bermejo, B. et al. (1997) Carboplatin-Based Versus Cisplatin-Based Chemotherapy in the Treatment of Surgically Incurable Advanced Bladder Carcinoma. Cancer 80: 1966-1972.[CrossRef][Medline] [Order article via Infotrieve]
  • Bellmunt, J., Von Der Maase, H., Mead, G.M., Heyer, J., Houede, N., Paz-Ares, L.G. et al. (2007a) Randomized Phase III Study Comparing Paclitaxel/ Cisplatin/Gemcitabine (Pcg) and Gemcitabine/ Cisplatin (Gc) in Patients with Locally Advanced (La) or Metastatic (M) Urothelial Cancer without Prior Systemic Therapy; Eortc30987/Intergroup Study. J Clin Oncol (Meeting Abstracts) 25: LBA5030.
  • Bellmunt Molins, J., Von Der Maase, H., Theodore, C., Demkov, T., Komyakow, B., Sengelov, L. et al. (2008) Randomised Phase III Trial of Vinflunine (V) Plus Best Supportive Care (B) Vs B Alone as 2 nd Line Therapy after a Platinum-Containing Regimen in Advanced Transitional Cell Carcinoma of the Urothelium (Tccu). J Clin Oncol (Meeting Abstracts) 26: 5028.
  • Bernardini, S., Fauconnet, S., Chabannes, E., Henry, P.C., Adessi, G. and Bittard, H. (2001) Serum Levels of Vascular Endothelial Growth Factor as a Prognostic Factor in Bladder Cancer. J Urol 166: 1275-1279.[CrossRef][Medline] [Order article via Infotrieve]
  • Bochner, B.H., Cote, R.J., Weidner, N., Groshen, S., Chen, S.C., Skinner, D.G. et al. (1995) Angiogenesis in Bladder Cancer: Relationship between Microvessel Density and Tumor Prognosis. J Natl Cancer Inst 87: 1603-1612.[Abstract/Free Full Text]
  • Boucher, Y., Kirkwood, J.M., Opacic, D., Desantis, M. and Jain, R.K. (1991) Interstitial Hypertension in Superficial Metastatic Melanomas in Humans. Cancer Res 51: 6691-6694.[Abstract/Free Full Text]
  • Campbell, S.C., Volpert, O.V., Ivanovich, M. and Bouck, N.P. (1998) Molecular Mediators of Angiogenesis in Bladder Cancer. Cancer Res 58: 1298-1304.[Abstract/Free Full Text]
  • Canoglu, A., Gogus, C., Beduk, Y., Orhan, D., Tulunay, O. and Baltaci, S. (2004) Microvessel Density as a Prognostic Marker in Bladder Carcinoma: Correlation with Tumor Grade, Stage and Prognosis. Int Urol Nephrol 36: 401-405.[CrossRef][Medline] [Order article via Infotrieve]
  • Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S. et al. (2000) Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by Zd-1839 (Iressa), an Epidermal Growth Factor Receptor-Selective Tyrosine Kinase Inhibitor. Clin Cancer Res 6: 2053-2063.[Abstract/Free Full Text]
  • Cordon-Cardo, C. (2008) Molecular Alterations Associated with Bladder Cancer Initiation and Progression. Scand J Urol Nephrol Suppl 218: 154-165.[Medline] [Order article via Infotrieve]
  • Crew, J.P., Fuggle, S., Bicknell, R., Cranston, D.W., De Benedetti, A. and Harris, A.L. (2000) Eukaryotic Initiation Factor-4 e in Superficial and Muscle Invasive Bladder Cancer and Its Correlation with Vascular Endothelial Growth Factor Expression and Tumour Progression. Br J Cancer 82: 161-166.[CrossRef][Medline] [Order article via Infotrieve]
  • Crew, J.P., Obrien, T., Bradburn, M., Fuggle, S., Bicknell, R., Cranston, D. et al. (1997) Vascular Endothelial Growth Factor Is a Predictor of Relapse and Stage Progression in Superficial Bladder Cancer. Cancer Res 57: 5281-5285.[Abstract/Free Full Text]
  • Culine, S., Theodore, C., De Santis, M., Bui, B., Demkow, T., Lorenz, J. et al. (2006) A Phase II Study of Vinflunine in Bladder Cancer Patients Progressing after First-Line Platinum-Containing Regimen. Br J Cancer 94: 1395-1401.[CrossRef][Medline] [Order article via Infotrieve]
  • Dickinson, A.J., Fox, S.B., Persad, R.A., Hollyer, J., Sibley, G.N. and Harris, A.L. (1994) Quantification of Angiogenesis as an Independent Predictor of Prognosis in Invasive Bladder Carcinomas. Br J Urol 74: 762-766.[Medline] [Order article via Infotrieve]
  • Dinney, C.P., Babkowski, R.C., Antelo, M., Perrotte, P., Liebert, M., Zhang, H.Z. et al. (1998a) Relationship among Cystectomy, Microvessel Density and Prognosis in Stage T1 Transitional Cell Carcinoma of the Bladder. J Urol 160: 1285-1290.[CrossRef][Medline] [Order article via Infotrieve]
  • Dinney, C.P., Bielenberg, D.R., Perrotte, P., Reich, R., Eve, B.Y., Bucana, C.D. et al. (1998b) Inhibition of Basic Fibroblast Growth Factor Expression, Angiogenesis, and Growth of Human Bladder Carcinoma in Mice by Systemic Interferon-Alpha Administration. Cancer Res 58: 808-814.[Abstract/Free Full Text]
  • Dogliotti, L., Carteni, G., Siena, S., Bertetto, O., Martoni, A., Bono, A. et al. (2007) Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial. Eur Urol 52: 134-141.[CrossRef][Medline] [Order article via Infotrieve]
  • Dominguez-Escrig, J.L., Kelly, J.D., Neal, D.E., King, S.M. and Davies, B.R. (2004) Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer. Clin Cancer Res 10: 4874-4884.[Abstract/Free Full Text]
  • Dreicer, R., Gustin, D.M., See, W.A. and Williams, R.D. (1996) Paclitaxel in Advanced Urothelial Carcinoma: Its Role in Patients with Renal Insufficiency and as Salvage Therapy. J Urol 156: 1606-1608.[CrossRef][Medline] [Order article via Infotrieve]
  • Dreicer, R., Li, H., Stein, M.N., Dipaola, R.P., Eleff, M., Roth, B.J. et al. (2008) Phase II Trial of Sorafenib in Advanced Carcinoma of the Urothelium (E 1804): A Trial of the Eastern Cooperative Oncology Group. J Clin Oncol (Meeting Abstracts) 26: 5083.
  • Dreicer, R., Li, S., Manola, J., Haas, N.B., Roth, B.J. and Wilding, G. (2007) Phase 2 Trial of Epothilone B Analog Bms-247550 (Ixabepilone) in Advanced Carcinoma of the Urothelium (E3800): A Trial of the Eastern Cooperative Oncology Group. Cancer 110: 759-763.[CrossRef][Medline] [Order article via Infotrieve]
  • Dreicer, R., Manola, J., Schneider, D.J., Schwerkoske, J.F., George, C.S., Roth, B.J. et al. (2003) Phase II Trial of Gemcitabine and Docetaxel in Patients with Advanced Carcinoma of the Urothelium: A Trial of the Eastern Cooperative Oncology Group. Cancer 97: 2743-2747.[CrossRef][Medline] [Order article via Infotrieve]
  • Dvorak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M. (1995) Vascular Permeability Factor/ Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis. Am J Pathol 146: 1029-1039.[Abstract]
  • Font, A., Taron, M., Costa, C., Layos, L., Perez-Roca, L., Sanchez, J. et al. (2008) Brca1 Mrna Expression in Patients (P) with Bladder Cancer Treated with Neoadjuvant Cisplatin-Based Chemotherapy. J Clin Oncol (Meeting Abstracts) 26: 5025.
  • Gallagher, D.J., Milowsky, M.I., Gerst, S.R., Iasonos, A., Riches, J., Boyle, M.G. et al. (2007) Phase II Study of Sunitinib in Patients (Pts) with Relapsed or Refractory Urothelial Carcinoma (Uc). J Clin Oncol (Meeting Abstracts) 25: 5080.
  • Galsky, M., Mironov, S., Iasonos, A., Scattergood, J., Boyle, M. and Bajorin, D. (2007) Phase II Trial of Pemetrexed as Second-Line Therapy in Patients with Metastatic Urothelial Carcinoma. Investigational New Drugs 25: 265-270.[CrossRef][Medline] [Order article via Infotrieve]
  • Gelmon, K.A., Latreille, J., Tolcher, A., Genier, L., Fisher, B., Forand, D. et al. (2000) Phase I Dose-Finding Study of a New Taxane, Rpr 109881 a, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients with Advanced Solid Tumors. J Clin Oncol 18: 4098-4108.[Abstract/Free Full Text]
  • Goddard, J.C., Sutton, C.D., Furness, P.N., O'byrne, K.J. and Kockelbergh, R.C. (2003) Microvessel Density at Presentation Predicts Subsequent Muscle Invasion in Superficial Bladder Cancer. Clin Cancer Res 9: 2583-2586.[Abstract/Free Full Text]
  • Grossman, H.B., Natale, R.B., Tangen, C.M., Speights, V.O., Vogelzang, N.J., Trump, D.L. et al. (2003) Neoadjuvant Chemotherapy Plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer. N Engl J Med 349: 859-866.[Abstract/Free Full Text]
  • Gutmann, R., Leunig, M., Feyh, J., Goetz, A.E., Messmer, K., Kastenbauer, E. et al. (1992) Interstitial Hypertension in Head and Neck Tumors in Patients: Correlation with Tumor Size. Cancer Res 52: 1993-1995.[Abstract/Free Full Text]
  • Hussain, M.H., Macvicar, G.R., Petrylak, D.P., Dunn, R.L., Vaishampayan, U.,Lara, Jr. P.N. et al. (2007) Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/Neu-Positive Urothelial Carcinoma: Results of a Multicenter Phase Ii National Cancer Institute Trial. J Clin Oncol 25: 2218-2224.[Abstract/Free Full Text]
  • Inoue, K., Kamada, M., Slaton, J.W., Fukata, S., Yoshikawa, C., Tamboli, P. et al. (2002) The Prognostic Value of Angiogenesis and Metastasis-Related Genes for Progression of Transitional Cell Carcinoma of the Renal Pelvis and Ureter. Clin Cancer Res 8: 1863-1870.[Abstract/Free Full Text]
  • Inoue, K., Slaton, J.W., Davis, D.W., Hicklin, D.J., Mcconkey, D.J., Karashima, T. et al. (2000a) Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody Dc101 and Paclitaxel. Clin Cancer Res 6: 2635-2643.[Abstract/Free Full Text]
  • Inoue, K., Slaton, J.W., Perrotte, P., Davis, D.W., Bruns, C.J., Hicklin, D.J. et al. (2000b) Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Imclone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma. Clin Cancer Res 6: 4874-4884.[Abstract/Free Full Text]
  • Izawa, J.I., Slaton, J.W., Kedar, D., Karashima, T., Perrotte, P., Czerniak, B. et al. (2001) Differential Expression of Progression-Related Genes in the Evolution of Superficial to Invasive Transitional Cell Carcinoma of the Bladder. Oncol Rep 8: 9-15.[Medline] [Order article via Infotrieve]
  • Jaeger, T.M., Weidner, N., Chew, K., Moore, D.H., Kerschmann, R.L., Waldman, F.M. et al. (1995) Tumor Angiogenesis Correlates with Lymph Node Metastases in Invasive Bladder Cancer. J Urol 154: 69-71.[CrossRef][Medline] [Order article via Infotrieve]
  • Li, J., Juliar, B., Yiannoutsos, C., Ansari, R., Fox, E., Fisch, M.J. et al. (2005) Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase Ii Hoosier Oncology Group Study. J Clin Oncol 23: 1185-1191.[Abstract/Free Full Text]
  • Lonn, U., Lonn, S., Friberg, S., Nilsson, B., Silfversward, C. and Stenkvist, B. (1995) Prognostic Value of Amplification of C-Erb-B2 in Bladder Carcinoma. Clin Cancer Res 1: 1189-1194.[Abstract]
  • Lorusso, V., Manzione, L., De Vita, F., Antimi, M., Selvaggi, F.P. and De Lena, M. (2000) Gemcitabine Plus Cisplatin for Advanced Transitional Cell Carcinoma of the Urinary Tract: A Phase Ii Multicenter Trial. J Urol 164: 53-56.[CrossRef][Medline] [Order article via Infotrieve]
  • Mccaffrey, J.A., Hilton, S., Mazumdar, M., Sadan, S., Kelly, W.K., Scher, H.I. et al. (1997) Phase II Trial of Docetaxel in Patients with Advanced or Metastatic Transitional-Cell Carcinoma. J Clin Oncol 15: 1853-1857.[Abstract/Free Full Text]
  • Meluch, A.A., Greco, F.A., Burris, 3rd H.A., O'rourke, T., Ortega, G., Steis, R.G. et al. (2001) Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 19: 3018-3024.[Abstract/Free Full Text]
  • Mita, A.C., Wang, D., Takimoto, C.H., Malseed, E., Nguyen, L., Rasmussen, E. et al. (2007) Amg 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adult Patients with Advanced Solid Tumors. J Clin Oncol (Meeting Abstracts) 25: 14033.
  • Nguyen, M., Watanabe, H., Budson, A.E., Richie, J.P. and Folkman, J. (1993) Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients. J Natl Cancer Inst 85: 241-242.[Free Full Text]
  • Nyman, D.W., Campbell, K.J., Hersh, E., Long, K., Richardson, K., Trieu, V. et al. (2005) Phase I and Pharmacokinetics Trial of Abi-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients with Advanced Nonhematologic Malignancies. J Clin Oncol 23: 7785-7793.[Abstract/Free Full Text]
  • Obrien, T., Cranston, D., Fuggle, S., Bicknell, R. and Harris, A.L. (1995) Different Angiogenic Pathways Characterize Superficial and Invasive Bladder Cancer. Cancer Res 55: 510-513.[Abstract/Free Full Text]
  • Oka, N., Yamamoto, Y., Takahashi, M., Nishitani, M., Kanayama, H.O. and Kagawa, S. (2005) Expression of Angiopoietin-1 and -2, and Its Clinical Significance in Human Bladder Cancer. BJU Int 95: 660-663.[CrossRef][Medline] [Order article via Infotrieve]
  • Paz-Ares, L., Bezares, S., Tabernero, J.M., Castellanos, D. and Cortes-Funes, H. (2003) Review of a Promising New Agent-Pemetrexed Disodium. Cancer 97: 2056-2063.[CrossRef][Medline] [Order article via Infotrieve]
  • Petrioli, R., Frediani, B., Manganelli, A., Barbanti, G., De Capua, B., De Lauretis, A. et al. (1996) Comparison between a Cisplatin-Containing Regimen and a Carboplatin- Containing Regimen for Recurrent or Metastatic Bladder Cancer Patients. A Randomized Phase II Study. Cancer 77: 344-351.[CrossRef][Medline] [Order article via Infotrieve]
  • Petrylak, D., Faulkner, J.R., Van Veldhuizen, P.J., Mansukhani, M. and Crawford, E.D. (2003) Evaluation of Zd1839 for Advanced Transitional Cell Carcinoma (Tcc) of the Urothelium: A Southwest Oncology Group Trial. Proc Am Soc Clin Oncol 22: Abstract 1619.
  • Philips, G.K., Halabi, S., Sanford, B.L., Bajorin, D. and Small, E.J. (2008) A Phase Ii Trial of Cisplatin, Fixed Dose-Rate Gemcitabine and Gefitinib for Advanced Urothelial Tract Carcinoma: Results of the Cancer and Leukaemia Group B 90102. BJU Int 101: 20-25.[Medline] [Order article via Infotrieve]
  • Philips, G.K., Halabi, S., Sanford, B.L., Bajorin, D. and Small, E.J. (2009) A Phase Ii Trial of Cisplatin (C), Gemcitabine (G) and Gefitinib for Advanced Urothelial Tract Carcinoma: Results of Cancer and Leukemia Group B (Calgb) 90102. Ann Oncol.
  • Rochester, M.A., Patel, N., Turney, B.W., Davies, D.R., Roberts, I.S., Crew, J. et al. (2007) The Type 1 Insulin-Like Growth Factor Receptor Is over-Expressed in Bladder Cancer. BJU Int 100: 1396-1401.[CrossRef][Medline] [Order article via Infotrieve]
  • Rosenberg, J.E., Halabi, S., Sanford, B.L., Himelstein, A.L., Atkins, J.N., Hohl, R.J. et al. (2008) Phase Ii Study of Bortezomib in Patients with Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma: Calgb 90207. Ann Oncol 19: 946-950.[Abstract/Free Full Text]
  • Saxman, S.B., Propert, K.J., Einhorn, L.H., Crawford, E.D., Tannock, I., Raghavan, D. et al. (1997) Long-Term Follow-up of a Phase Iii Intergroup Study of Cisplatin Alone or in Combination with Methotrexate, Vinblastine, and Doxorubicin in Patients with Metastatic Urothelial Carcinoma: A Cooperative Group Study. J Clin Oncol 15: 2564-2569.[Abstract/Free Full Text]
  • Shen, S.S., Smith, C.L., Hsieh, J.T., Yu, J., Kim, I.Y., Jian, W. et al. (2006) Expression of Estrogen Receptors-Alpha and -Beta in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue. Cancer 106: 2610-2616.[CrossRef][Medline] [Order article via Infotrieve]
  • Sirotnak, F.M., Zakowski, M.F., Miller, V.A., Scher, H.I. and Kris, M.G. (2000) Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced by Coadministration of Zd1839 (Iressa), an Inhibitor of Egfr Tyrosine Kinase. Clin Cancer Res 6: 4885-4892.[Abstract/Free Full Text]
  • Slaton, J.W., Millikan, R., Inoue, K., Karashima, T., Czerniak, B., Shen, Y. et al. (2004) Correlation of Metastasis Related Gene Expression and Relapse-Free Survival in Patients with Locally Advanced Bladder Cancer Treated with Cystectomy and Chemotherapy. J Urol 171: 570-574.[CrossRef][Medline] [Order article via Infotrieve]
  • Sonpavde, G., Jian, W., Liu, H., Wu, M.F., Shen, S.S. and Lerner, S.P. (2008) Sunitinib Malate Is Active against Human Urothelial Carcinoma and Enhances the Activity of Cisplatin in a Preclinical Model. Urol Oncol.
  • Sonpavde, G., Okuno, N., Weiss, H., Yu, J., Shen, S.S., Younes, M. et al. (2007) Efficacy of Selective Estrogen Receptor Modulators in Nude Mice Bearing Human Transitional Cell Carcinoma. Urology 69: 1221-1226.[CrossRef][Medline] [Order article via Infotrieve]
  • Sridhar, S.S., Winquist, E. and Eisen, A. (2008) A Phase II Study of First-Line Sorafenib (Bay 43-9006) in Advanced or Metastatic Urothelial Cancer. A Trial of the Pmh Phase Ii Consortium. Proceedings of the 2008 Genitourinary Cancers Symposium: Abstract #340.
  • Sriplakich, S., Jahnson, S. and Karlsson, M.G. (1999) Epidermal Growth Factor Receptor Expression: Predictive Value for the Outcome after Cystectomy for Bladder Cancer? BJU Int 83: 498-503.[Medline] [Order article via Infotrieve]
  • Sternberg, C.N., Calabro, F., Pizzocaro, G., Marini, L., Schnetzer, S. and Sella, A. (2001) Chemotherapy with an Every-2-Week Regimen of Gemcitabine and Paclitaxel in Patients with Transitional Cell Carcinoma Who Have Received Prior Cisplatin-Based Therapy. Cancer 92: 2993-2998.[CrossRef][Medline] [Order article via Infotrieve]
  • Sternberg, C.N., De Mulder, P., Schornagel, J.H., Theodore, C., Fossa, S.D., Van Oosterom, A.T. et al. (2006) Seven Year Update of an Eortc Phase Iii Trial of High-Dose Intensity M-Vac Chemotherapy and G-Csf Versus Classic M-Vac in Advanced Urothelial Tract Tumours. European Journal of Cancer 42: 50-54.[CrossRef][Medline] [Order article via Infotrieve]
  • Sweeney, C.J., Roth, B.J., Kabbinavar, F.F., Vaughn, D.J., Arning, M., Curiel, R.E. et al. (2006) Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium. J Clin Oncol 24: 3451-3457.[Abstract/Free Full Text]
  • Tanaka, Y., Kawamata, H., Fujimoto, K. and Oyasu, R. (1997) Angiogenesis Inhibitor Tnp-470 Suppresses Tumorigenesis in Rat Urinary Bladder. J Urol 157: 683-688.[CrossRef][Medline] [Order article via Infotrieve]
  • Theodore, C., Bidault, F., Bouvet-Forteau, N., Abdelatif, M., Fizazi, K., Di Palma, M. et al. (2006) A Phase II Monocentric Study of Oxaliplatin in Combination with Gemcitabine (Gemox) in Patients with Advanced/Metastatic Transitional Cell Carcinoma (Tcc) of the Urothelial Tract. Ann Oncol 17: 990-994.[Abstract/Free Full Text]
  • Vaughn, D.J., Broome, C.M., Hussain, M., Gutheil, J.C. and Markowitz, A.B. (2002) Phase II Trial of Weekly Paclitaxel in Patients with Previously Treated Advanced Urothelial Cancer. J Clin Oncol 20: 937-940.[Abstract/Free Full Text]
  • Von Der Maase, H., Lehmann, J., Gravis, G., Joensuu, H., Geertsen, P.F., Gough, J. et al. (2006) A Phase II Trial of Pemetrexed Plus Gemcitabine in Locally Advanced and/or Metastatic Transitional Cell Carcinoma of the Urothelium. Ann Oncol 17: 1533-1538.[Abstract/Free Full Text]
  • Von Der Maase, H., Sengelov, L., Roberts, J.T., Ricci, S., Dogliotti, L., Oliver, T. et al. (2005) Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, with Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients with Bladder Cancer. J Clin Oncol 23: 4602-4608.[Abstract/Free Full Text]
  • Willett, C.G., Boucher, Y., Di Tomaso, E., Duda, D.G., Munn, L.L., Tong, R.T. et al. (2004) Direct Evidence That the Vegf-Specific Antibody Bevacizumab Has Antivascular Effects in Human Rectal Cancer. Nat Med 10: 145-147.[CrossRef][Medline] [Order article via Infotrieve]
  • Winquist, E., Vokes, E., Moore, M.J., Schumm, L.P., Hoving, K. and Stadler, W.M. (2005) A Phase II Study of Oxaliplatin in Urothelial Cancer. Urol Oncol 23: 150-154.[Medline] [Order article via Infotrieve]
  • Wu, W., Shu, X., Hovsepyan, H., Mosteller, R.D. and Broek, D. (2003) Vegf Receptor Expression and Signaling in Human Bladder Tumors. Oncogene 22: 3361-3370.[CrossRef][Medline] [Order article via Infotrieve]
  • Wulfing, C., Machiels, J.P., Richel, D., Grimm, M.O., Treiber, U., De Groot, M. et al. (2005) A Single Arm, Multicenter, Open Label, Phase Ii Study of Lapatinib as 2 l Treatment of Pts with Locally Advanced/ Metastatic Transitional Cell Carcinoma (Tcc) of the Urothelial Tract. J Clin Oncol (Meeting Abstracts) 23: 4594.
  • Xia, G., Kumar, S.R., Hawes, D., Cai, J., Hassanieh, L., Groshen, S. et al. (2006) Expression and Significance of Vascular Endothelial Growth Factor Receptor 2 in Bladder Cancer. J Urol 175: 1245-1252.[CrossRef][Medline] [Order article via Infotrieve]
  • Yang, C.C., Chu, K.C. and Yeh, W.M. (2004) The Expression of Vascular Endothelial Growth Factor in Transitional Cell Carcinoma of Urinary Bladder Is Correlated with Cancer Progression. Urol Oncol 22: 1-6.[Medline] [Order article via Infotrieve]
  • Zhu, K., Pino, M., Siefker-Radtke, A.O., Shalinsky, D., Hu-Lowe, D. and Mcconkey, D.J. (2006) Ag-013736, a Novel Vegf Receptor and Pdgf Receptor Inhibitor with Potent Activity against Human Bladder Carcinoma in Vitro and in Vivo. J Clin Oncol (Meeting Abstracts) 24: 13109.

Therapeutic Advances in Medical Oncology, Vol. 1, No. 1, 37-50 (2009)
DOI: 10.1177/1758834009337776
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sonpavde, G.
Right arrow Articles by Rosenberg, J. E.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?